Vaxart (VXRT)

• Market cap: $160M
• 1 day: 30.73%
• 5 days: 75.50%
• 1 month: 68.95%
• 3 months: 35.73%
• 6 months: 18.58%
• Year to date: -2.32%
• 1 year: -6.39%
• 5 years: -71.46%
• 10 years: -65.76%
• Sector: Healthcare
• Industry: Biotechnology

About: Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines based on its Vector Adjuvant Antigen Standardized Technology to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States.

Employees: 105

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

15% more call options, than puts

Call options by funds: $38K | Put options by funds: $33K

0% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 12

1% less funds holding

Funds holding: 92 [Q4 2024] → 91 (-1) [Q1 2025]

3.73% less ownership

Funds ownership: 15.71% [Q4 2024] → 11.98% (-3.73%) [Q1 2025]

38% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 24

53% less capital invested

Capital invested by funds: $23.7M [Q4 2024] → $11.1M (-$12.5M) [Q1 2025]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $2 185% upside
• Avg. target: $2 185% upside
• High target: $2 185% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

B. Riley Securities Mayank Mamtani

185% upside $2

Buy Maintained

27 Mar 2025